Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $-4.12M.
ENTERPRISE VALUE (EV)
$-4.12M
GRI Bio, Inc.
Market Cap
$4.11M
Enterprise Value (EV)
$-4.12M
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| GRI Bio, Inc. (GRI) | $4.11M | $-4.12M |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.12M | $3.93M |
| Ernexa Therapeutics Inc. (ERNA)vs › | $4.08M | N/A |
| Aptevo Therapeutics Inc. (APVO)vs › | $4.05M | N/A |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.22M | $248070.00 |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.33M | $4.04M |
| PharmaCyte Biotech, Inc. (PMCB)vs › | $4.40M | N/A |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.55M | $132258.00 |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.68M | $886634.00 |
| Nexalin Technology, Inc. (NXL)vs › | $3.53M | $2.52M |
Market Cap
$4.11M
Total Debt
$0.00
Cash
$8.23M
Enterprise Value
$-4.12M
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
